Crowd­ed rheuma­toid arthri­tis cat­e­go­ry gets JAK re­al­i­ty check, while TNF stal­warts con­tin­ue to dom­i­nate: study

The FDA’s black box la­bel slap on JAK rheuma­toid arthri­tis brands last year hit where it hurt – in class rep­u­ta­tion and pre­scrip­tions. But Pfiz­er’s Xel­janz, in the cen­ter of the safe­ty storm, has been par­tic­u­lar­ly hard hit.

Al­most half (49%) of rheuma­tol­o­gists de­creased pre­scrip­tions of Xel­janz for pa­tients over the past three months while on­ly 10% in­creased its use, ac­cord­ing to Spher­ix Glob­al In­sights’ most re­cent quar­ter­ly study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER